Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

被引：29

作者：

Katodritou, Eirini ^{[1
]}

Verrou, Evgenia ^{[1
]}

Gastari, Vassiliki ^{[1
]}

Hadjiaggelidou, Christina ^{[1
]}

Terpos, Evangelos ^{[1
]}

Zervas, Konstantinos ^{[1
]}

机构：

[1] Theagenion Canc Ctr, Thessaloniki, Greece

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 07期

关键词：

primary plasma cell leukemia; cytogenetics; immunophenotype; bortezomib;

D O I：

10.1016/j.leukres.2007.11.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Plasma cell leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasias. Its special biological characteristics may play an important role in the poor outcome when treated with conventional therapy or even with stem cell transplantation. New treatment approaches based on the biology of this disease are mandatory. Here we present three cases of primary PCL with adverse cytogenetics (deletion 13q14 and translocation 4; 14) and specific immunophenotypic features (CD27 antigen strong expression) in which excellent response and sustained remission was achieved with the combination of bortezomib and dexamethasone. The possible role of these biological characteristics is been analyzed. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1153 / 1156

页数：4

共 9 条

[1] Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia:: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique [J].

Avet-Loiseau, H ;

Daviet, A ;

Brigaudeau, C ;

Callet-Bauchu, E ;

Terré, C ;

Lafage-Pochitaloff, M ;

Désangles, F ;

Ramond, S ;

Talmant, P ;

Bataille, R .

BLOOD, 2001, 97 (03) :822-825

[2] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[3] Bortezomib is effective in primary plasma cell leukemia [J].

Finnegan, Damian P. J. ;

Kettle, Paul ;

Drake, Mary ;

Matthews, Christine ;

Alexander, H. Denis ;

Popat, Rakesh ;

Cavanagh, Jamie D. ;

Wachsman, William ;

Morris, T. C. M. .

LEUKEMIA & LYMPHOMA, 2006, 47 (08) :1670-1673

[4] Managing plasma cell leukemia [J].

Gertz, Morie A. .

LEUKEMIA & LYMPHOMA, 2007, 48 (01) :5-6

[5] CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases [J].

Guikema, JEJ ;

Vellenga, E ;

Abdulahad, WH ;

Hovenga, S ;

Bos, NA .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (03) :299-308

[6]

Kyle RA, 2003, BRIT J HAEMATOL, V121, P749

[7] Proteasome inhibitors:: antitumor effects and beyond [J].

Nencioni, A. ;

Gruenebach, F. ;

Patrone, F. ;

Ballestrero, A. ;

Brossart, P. .

LEUKEMIA, 2007, 21 (01) :30-36

[8] The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma [J].

Pellat-Deceunynck, C ;

Barillé, S ;

Jego, G ;

Puthier, D ;

Robillard, N ;

Pineau, D ;

Rapp, MJ ;

Harousseau, JL ;

Amiot, M ;

Bataille, R .

LEUKEMIA, 1998, 12 (12) :1977-1982

[9] Bortezomib in relapsed multiple myeloma:: response rates and duration of response are independent of a chromosome 13q-deletion [J].

Sagaster, V. ;

Ludwig, H. ;

Kaufmann, H. ;

Odelga, V. ;

Zojer, N. ;

Ackermann, J. ;

Kueenburg, E. ;

Wieser, R. ;

Zielinski, C. ;

Drach, J. .

LEUKEMIA, 2007, 21 (01) :164-168

← 1 →